Effects of different antidepressant treatments on the core of depression

Dialogues in Clinical Neuroscience

Volumn 10, Issue 3, 2008, Pages 309-320

  Baghai, Thomas C ^a   Eser, Daniela ^a   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antidepressant treatment; Depression; Electroconvulsive therapy; Melancholia; Pharmacological treatment

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; DULOXETINE; ESCITALOPRAM; HYPERICUM PERFORATUM EXTRACT; HYPNOTIC AGENT; LAMOTRIGINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADJUSTMENT DISORDER; ARTICLE; ATYPICAL DEPRESSION; BIPOLAR DEPRESSION; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL; COMORBIDITY; DELUSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; ENDOGENOUS DEPRESSION; HALLUCINATION; HAMILTON SCALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INCREASED APPETITE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR DEPRESSION; MELANCHOLIA; METABOLIC SYNDROME X; MONOTHERAPY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHOTOTHERAPY; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR RETARDATION; PSYCHOSIS; RECURRENT DISEASE; RESTLESSNESS; SEASONAL AFFECTIVE DISORDER; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOMATOLOGY; TREATMENT PLANNING; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMANS;

EID: 55449126375     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Burke MJ, Preskorn SH. Short term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, ed. Psychopharmacology: the Fourth Generation of Progress. New York, NY. Raven Press, 1995:1053-1065.
2. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;15;48:813-829.
3. Bolwig TG, Madsen TM. Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis. Acta Psychiatrica Scandinavica. 2007;115:130-135.
4. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry. 2002;7(suppl 1):S29-S34.
5. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
6. Schule C, Baghai TC, Rupprecht R. [New insights into the pathogenesis and pathophysiology of depression). Nervenarzt. 2007;78(suppl 3:531-547.
7. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85:335-353.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
9. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization; 1992.
10. World Health Organization. Depression. WHO report on mental health. 2005. Available at: URL: http://www.who.int/mental_health/management/ depression/definition/en/.
11. Bauer M, Whybrow PC, Angst J, Versiani M, Möller H-J, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of unipolar depressive disorder. Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:4-43.
12. Shorter E. The doctrine of the two depressions in historical perspective. Acta Psychiatr Scand. 2007;115:5-13.
13. Fink M, Taylor MA. Resurrecting melancholia. Acta Psychiatr Scand. 2007;115:14-20.
14. Parker G. Defining melancholia: the primacy of psychomotor disturbance. Acta Psychiatr Scand. 2007;115:21-30.
15. Khan AY, Carrithers J, Preskorn SH, et al. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatry. 2006;18:91-98.
16. Stewart JW, McGrath PJ, Quitkin FM, Klein DF. Atypical depression: current status and relevance to melancholia. Acta Psychiatr Scand. 2007;115:58-71.
17. Henkel V, Mergl R, Allgaier AK, Kohnen R, Möller HJ, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 2006 30;141:89-101.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Steinmeyer EM, Moller HJ. Facet theoretic analysis of the Hamilton-D scale. J Affect Disord. 1992;25:53-61.
20. Bech P, Allerup P, Gram LF, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63:290-299.
21. Lecrubier Y, Bech P. The Ham D is more homogenous and as sensitive as the Ham D. Eur Psychiatry. 2007;22:252-255.
22. Coryell W. The facets of melancholia. Acta Psychiatr Scand. 2007;115:31-36.
23. Brown WA. Treatment response in melancholia. Acta Psychiatr Scand. 2007;115:125-129.
24. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the EDCEU Assessment Battery, 2 Rev. Chevy Chase, MID: NIM; 1976:12-1-12-6.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
26. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007;22:283-291.
27. Azorin JM, Llorca PM, Despiegel N, Verpillat P. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Encephale. 2004;30:158-166.
28. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Available at: www.nice.org.uk/ pdf/CG023quickrefguide.pdf. 2004;Clinical Guideline 23.
29. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry. 2001;34(suppl 1):551-S55.
30. Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998;31(suppl 1):54-59.
31. Gupta RK, Moller HJ. St. John's Wort. An option for the primary care treatment of depressive patients? Eur Arch Psychiatry Clin Neurosci. 2003;253:140-148.
32. Uebelhack R, Gruenwald J, Graubaum HJ, Busch R. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 2004;21:265-275.
33. Laakmann G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T. Are benzodiazepines antidepressants? Psychopharmacology (Berl). 1996;124:291-292.
34. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
35. Shelton RC, Andorn AC, Mallinckrodt CH, et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol. 2007;22:348-355.
36. Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr Psychiatry. 2000;41(suppl 1):133-137.
37. Hegerl U, Pfeiffer-Gerschel T, Althaus D. [Elements for the effective treatment of patients with depressive disorders at the primary care level]. MMW Fortschr Med. 2004 24;146. Spec No 2:10, 12-0, 14.
38. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
39. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. Are all antidepressants really the same? the case of fluoxetine: a systematic review. J Clin Psychiatry. 2006;67:850-864.
40. Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7(suppl 1):11-17.
41. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1993;28:105-116.
42. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007;22:323-329.
43. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
44. Sartorius N, Baghai TC, Baldwin DS, et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol. 2007;10(suppl 1):S1-S207.
45. Coryell W. Psychotic depression. J Clin Psychiatry. 1996;57(suppl 3):27-31.
46. Mulsant BH, Sweet RA, Rosen J, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001;62:597-604.
47. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993;54:338-342.
48. Anton RF, Jr., Burch EA, Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990;147:1203-1208.
49. Zanardi R, Franchini L, Gasperini M, Smeraldi E, Perez J. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study. Int Clin Psychopharmacol. 1997;12:195-197.
50. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153:1631-1633.
51. Coryell W. The treatment of psychotic depression. J Clin Psychiatry, 1998;59(suppl 1):22-27.
52. Birkenhager TK, Renes JW, Pluijms EM. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. J Clin Psychiatry, 2004;65:87-91.
53. American Psychiatric Association Committee on Electroconvulsive Therapy: Weiner RD, Coffey CE, et al. The Practice of Electroconvulsive Therapy, 2nd ed. Washington, DC: American Psychiatric Association; 2001.
54. Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry. 2003;48:440-448.
55. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry. 1983;140:318-322.
56. Starkstein SE, Petracca G, Teson A, et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry. 1996;60:326-32.
57. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233-1241.
58. Fink M. Catatonia and DSM-IV. Convuls Ther. 1992;8:159-162.
59. Rohland BM, Carroll BT, Jacoby RG. ECT in the treatment of the catatonic syndrome. J Affect Disord. 1993;29:255-261.
60. Fink M. Is catatonia a primary indication for ECT? Convuls Ther. 1990;6:1-4.
61. Akiskal H, Bourgeois ML, Angst J, Post R, Möller H-J, Hirschfeld RM. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59(suppl 1:5-30.
62. Cassano GB, Musetti L, Perugi G, et al. A proposed new approach to the clinical subclassification of depressive illness. Pharmacopsychiatry. 1988;21:19-23.
63. Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord. 2006;92:45-54.
64. Goldberg JF. When do antidepressants worsen the course of bipolar disorder? J Psychiatr Pract. 2003;9:181-194.
65. Angst J. Do many patients with depression suffer from bipolar disorder? Can J Psychiatry. 2006;51:3-5.
66. Patten SB. Does almost everybody suffer from a bipolar disorder? Can J Psychiatry. 2006;51:6-8.
67. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537-1547.
68. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55:391-393.
69. Grunze H, Kasper 5, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3:115-124.
70. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549-550.
71. Yatham LN. Atypical antipsychotics for bipolar disorder. Psychiatr Clin North Am. 2005;28:325-347.
72. Möller HJ, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci. 2006;256:1-16.
73. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol. 2006;16:281-287.
74. Rocca P, Fonzo V, Ravizza L, et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002;70:313-317.
75. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of sub-syndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.
76. Pezawas L, Stamenkovic M, Kasper S. [Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy]. Nervenarzt. 2001;72:169-180.
77. Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D, Montgomery SA. Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. Eur Arch Psychiatry Clin Neurosci. 1994;244:211-215.
78. Angst J, Dobler-Mikola A. The Zurich Study-a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression. Eur Arch Psychiatry Neurol Sci. 1985;234:408-416.
79. Pezawas L, Angst J, Kasper S. Recurrent brief depression revisited. Int Rev Psychiatry. 2005;17:63-70.
80. Kasper S, Rogers SL, Madden PA, Joseph-Vanderpool JR, Rosenthal NE. The effects of phototherapy in the general population. J Affect Disord. 1990;18:211-219.
81. Rosenthal NE, Sack DA, Carpenter CJ, Parry BL, Mendelson WB, Wehr TA. Antidepressant effects of light in seasonal affective disorder. Am J Psychiatry. 1985;142:163-170.
82. Praschak-Rieder N, Neumeister A, Hesselmann B, Willeit M, Barnas C, Kasper S. Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases. J Clin Psychiatry. 1997;58:389-392.
83. Fountoulakis KN, Iacovides A, Nimatoudis I, Kaprinis G, Ierodiakonou C. Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression. Eur Psychiatry. 1999;14:426-433.
84. Novick JS, Stewart JW, Wisniewski SR, et al. Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR D. J Clin Psychiatry. 2005;66:1002-1011.
85. Henkel V, Mergl R, Coyne JC, et al. Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. J Affect Disord. 2004; 83:237-242.
86. Angst J, Gamma A, Benazzi F, Ajdacic V, Rössler W. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatrica Scandinavica. 2007;115:72-84.
87. Sogaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol. 1999;13:406-414.
88. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med. 1994. 19;97(6A):24S-32S.
89. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. 2007;115:104-115.
90. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(suppl 17):28-31.
91. Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol. 2003;23:78-86.
92. Riemann D, Voderholzer U, Cohrs S, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry. 2002;35:165-174.
93. Leproult R, Van OA, L'hermite-Baleriaux M, Van CE, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005;63:298-304.
94. Loo H, Dalery J, Macher JP, Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders]. Encephale. 2002;28:356-362.
95. Loo H, Dalery J, Macher JP, Payen A. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders]. Encephale. 2003;29:165-171.
96. Fava M. Somatic symptoms, depression, and antidepressant treatment. Clin Psychiatry. 2002;63:305-307.
97. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999 28;341:1329-1335.
98. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005;17:CD005454.
99. Mattia C, Paoletti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 2002;68:105-114.
100. Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther. 2005;12:431-438.
101. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.
102. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry. 2003;64(suppl 13):26-29.
103. Hameed U, Schwartz TL, Malhotra K, West RL, Bertone F. Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression. Ann Clin Psychiatry. 2005;17:77-81.